Halozyme Therapeutics (HALO) Share-based Compensation Growth (1y) (2011 - 2026)
Halozyme Therapeutics (HALO) Share-based Compensation Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,561.01 Bn | 66,560.72 Bn | - | 118.32% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 469.79 Bn | 465.00 Bn | 1.35 Bn | -40.86% |
| 5 | Vertex Pharmaceuticals | 122.95 Bn | 115.70 Bn | 2.59 Bn | 0.18% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.30 Bn | 3.31 Bn | 5,886.05% |
| 7 | Belite Bio | 62.62 Bn | 62.62 Bn | - | - |
| 8 | Argenx Se | 56.18 Bn | 50.99 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Halozyme Therapeutics | 9.75 Bn | 9.43 Bn | 297.47 Mn | -98.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -98.41% |
| Dec 31, 2025 | 346.17% |
| Sep 30, 2025 | -101.01% |
| Jun 30, 2025 | -1,117.50% |
| Mar 31, 2025 | 2,082.62% |
| Dec 31, 2024 | 742.17% |
| Sep 30, 2024 | 17,404.02% |
| Jun 30, 2024 | 54.83% |
| Mar 31, 2024 | 20.44% |
| Dec 31, 2023 | -95.93% |
| Sep 30, 2023 | -76.89% |
| Jun 30, 2023 | 113.94% |
| Mar 31, 2023 | -91.44% |
| Dec 31, 2022 | 317.64% |
| Sep 30, 2022 | -95.10% |
| Jun 30, 2022 | 1.74% |
| Mar 31, 2022 | -3.68% |
| Dec 31, 2021 | -189.37% |
| Sep 30, 2021 | 274.97% |
| Jun 30, 2021 | -163.97% |